Medivation Inc.'s second-quarter revenue miss is unlikely to dampen big pharma's interest in the firm as a takeout target, in the view of most analysts, though company management steered clear of any M&A talk during its earnings call, focusing instead on the commercial growth of Xtandi (enzalutamide) in prostate cancer and touting its late-stage PARP inhibitor, talazoparib.